An 8-Week Course of Bifidobacterium longum 35624
Abdominal pain
Bifidobacterium longum 35624®
Irritable bowel syndrome
Post-market clinical follow-up study
Probiotics
Journal
Probiotics and antimicrobial proteins
ISSN: 1867-1314
Titre abrégé: Probiotics Antimicrob Proteins
Pays: United States
ID NLM: 101484100
Informations de publication
Date de publication:
13 Sep 2023
13 Sep 2023
Historique:
accepted:
22
08
2023
medline:
13
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
aheadofprint
Résumé
Irritable bowel syndrome (IBS) is one of the disorders most frequently diagnosed by gastroenterologists. Probiotics are promising tools for the management of IBS. The objective of the present study was to evaluate the effectiveness and tolerability of a probiotic (Bifidobacterium longum 35624
Identifiants
pubmed: 37702965
doi: 10.1007/s12602-023-10151-w
pii: 10.1007/s12602-023-10151-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Soares RL (2014) Irritable bowel syndrome: a clinical review. World J Gastroenterol 20:12144–12160
pubmed: 25232249
pmcid: 4161800
doi: 10.3748/wjg.v20.i34.12144
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al (2021) Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology 160(99–114):e3
Lacy BE, Patel NK (2017) Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 6:99
pubmed: 29072609
pmcid: 5704116
doi: 10.3390/jcm6110099
Black CJ, Ford AC (2020) Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 17:473–486
pubmed: 32296140
doi: 10.1038/s41575-020-0286-8
Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA et al (2016) Irritable bowel syndrome. Nat Rev Dis Primers 2:16014
pubmed: 27159638
pmcid: 5001845
doi: 10.1038/nrdp.2016.14
Galica AN, Galica R, Dumitrascu DL (2022) Diet, fibers, and probiotics for irritable bowel syndrome. J Med Life 15:174–179
pubmed: 35419092
pmcid: 8999090
doi: 10.25122/jml-2022-0028
Ghaffari P, Shoaie S, Nielsen LK (2022) Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions. J Transl Med 20:173
pubmed: 35410233
pmcid: 9004034
doi: 10.1186/s12967-022-03365-z
Scaciota ACL, Matos D, Rosa MMB, Colovati MES, Bellotto E, Martimbianco ALC (2021) Interventions for the treatment of irritable bowel syndrome: a review of Cochrane systematic reviews. Arq Gastroenterol 58:120–126
pubmed: 33909790
doi: 10.1590/s0004-2803.202100000-20
Xie CR, Tang B, Shi YZ, Peng WY, Ye K, Tao QF et al (2022) Low FODMAP diet and probiotics in irritable bowel syndrome: a systematic review with network meta-analysis. Front Pharmacol 13:853011
pubmed: 35355730
pmcid: 8959572
doi: 10.3389/fphar.2022.853011
Bosman M, Elsenbruch S, Corsetti M, Tack J, Simren M, Winkens B et al (2021) The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 6:459–473
pubmed: 33765447
doi: 10.1016/S2468-1253(21)00023-6
Rodino-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garcia R, Santos J (2018) A review of microbiota and irritable bowel syndrome: future in therapies. Adv Ther 35:289–310
pubmed: 29498019
pmcid: 5859043
doi: 10.1007/s12325-018-0673-5
Zhou Q, Zhang B, Verne GN (2009) Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 146:41–46
pubmed: 19595511
pmcid: 2763174
doi: 10.1016/j.pain.2009.06.017
Ohland CL, Macnaughton WK (2010) Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298:G807–G819
pubmed: 20299599
doi: 10.1152/ajpgi.00243.2009
Satish Kumar L, Pugalenthi LS, Ahmad M, Reddy S, Barkhane Z, Elmadi J (2022) Probiotics in irritable bowel syndrome: a review of their therapeutic role. Cureus 14:e24240
pubmed: 35602835
pmcid: 9116469
Wiegers C, Veerman MA, Brummer RJ, Larsen OFA (2022) Reviewing the state of the art of probiotics as clinical modalities for brain-gut-microbiota axis associated disorders. Front Microbiol 13:1053958
pubmed: 36504794
pmcid: 9732675
doi: 10.3389/fmicb.2022.1053958
Zhang T, Zhang C, Zhang J, Sun F, Duan L (2022) Efficacy of probiotics for irritable bowel syndrome: a systematic review and network meta-analysis. Front Cell Infect Microbiol 12:859967
pubmed: 35433498
pmcid: 9010660
doi: 10.3389/fcimb.2022.859967
Barbara G, Cremon C, Bellini M, Corsetti M, Di Nardo G, Falangone F et al (2022) Italian guidelines for the management of irritable bowel syndrome: Joint Consensus from the Italian Societies of: Gastroenterology and Endoscopy (SIGE), Neurogastroenterology and Motility (SINGEM), Hospital Gastroenterologists and Endoscopists (AIGO), Digestive Endoscopy (SIED), General Medicine (SIMG), Gastroenterology, Hepatology and Pediatric Nutrition (SIGENP) and Pediatrics (SIP). Dig Liver Dis 55:187–207
pubmed: 36517261
doi: 10.1016/j.dld.2022.11.015
Fukudo S, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T et al (2021) Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol 56:193–217
pubmed: 33538894
pmcid: 7932982
doi: 10.1007/s00535-020-01746-z
Gwee KA, Lee WW, Ling KL, Ooi CJ, Quak SH, Dan YY et al (2018) Consensus and contentious statements on the use of probiotics in clinical practice: a south east Asian gastro-neuro motility association working team report. J Gastroenterol Hepatol 33:1707–1716
pubmed: 29697855
doi: 10.1111/jgh.14268
Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD et al (2021) ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol 116:17–44
pubmed: 33315591
doi: 10.14309/ajg.0000000000001036
Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L et al (2019) Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol 2:6–29
pubmed: 31294724
pmcid: 6507291
doi: 10.1093/jcag/gwy071
Quigley EM, Fried M, Gwee KA, Khalif I, Hungin AP, Lindberg G et al (2016) World Gastroenterology Organisation global guidelines irritable bowel syndrome: a global perspective update September 2015. J Clin Gastroenterol 50:704–713
pubmed: 27623513
doi: 10.1097/MCG.0000000000000653
Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M et al (2021) British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 70:1214–1240
pubmed: 33903147
doi: 10.1136/gutjnl-2021-324598
Healy S, Casey M, Kiely B, Quigley EM, Shanahan F, Murphy EF (2017) 68 The bifidobacterium longum 35624 culture transits in high numbers through the human gut. Gut 66:A25
Altmann F, Kosma P, O’Callaghan A, Leahy S, Bottacini F, Molloy E et al (2016) Genome analysis and characterisation of the exopolysaccharide produced by Bifidobacterium longum subsp. longum 35624. PLoS One 11:e0162983
pubmed: 27656878
pmcid: 5033381
doi: 10.1371/journal.pone.0162983
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L et al (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101:1581–1590
pubmed: 16863564
doi: 10.1111/j.1572-0241.2006.00734.x
O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K et al (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551
pubmed: 15765388
doi: 10.1053/j.gastro.2004.11.050
Sabaté JM, Iglicki F (2022) Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol 28:732–744
pubmed: 35317278
pmcid: 8891724
doi: 10.3748/wjg.v28.i7.732
Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A et al (2012) World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 46:468–481
pubmed: 22688142
doi: 10.1097/MCG.0b013e3182549092
Charbonneau D, Gibb RD, Quigley EM (2013) Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 4:201–211
pubmed: 23549409
pmcid: 3669165
doi: 10.4161/gmic.24196
Yao S, Zhao Z, Wang W, Liu X (2021) Bifidobacterium Longum: protection against inflammatory bowel disease. J Immunol Res 2021:8030297
pubmed: 34337079
pmcid: 8324359
doi: 10.1155/2021/8030297
Rueda-Robles A, Rodriguez-Lara A, Meyers MS, Saez-Lara MJ, Alvarez-Mercado AI (2022) Effect of probiotics on host-microbiota in bacterial infections. Pathogens 11:986
pubmed: 36145418
pmcid: 9500725
doi: 10.3390/pathogens11090986
Konieczna P, Groeger D, Ziegler M, Frei R, Ferstl R, Shanahan F et al (2012) Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 61:354–366
pubmed: 22052061
doi: 10.1136/gutjnl-2011-300936
Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B et al (2013) Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 4:325–339
pubmed: 23842110
pmcid: 3744517
doi: 10.4161/gmic.25487
Miller LE (2014) Study design considerations for irritable bowel syndrome clinical trials. Ann Gastroenterol 27:338–345
pubmed: 25330749
pmcid: 4188930
Arlett P, Kjaer J, Broich K, Cooke E (2022) Real-world evidence in EU medicines regulation: enabling use and establishing value. Clin Pharmacol Ther 111:21–23
pubmed: 34797920
doi: 10.1002/cpt.2479
Francis CY, Morris J, Whorwell PJ (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11:395–402
pubmed: 9146781
doi: 10.1046/j.1365-2036.1997.142318000.x
Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L et al (2005) The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 17:332–340
pubmed: 15916620
doi: 10.1111/j.1365-2982.2005.00650.x
Ford AC, Moayyedi P (2010) Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 32:144–158
pubmed: 20412064
doi: 10.1111/j.1365-2036.2010.04328.x
van der Geest AM, Schukking I, Brummer RJM, van de Burgwal LHM, Larsen OFA (2022) Comparing probiotic and drug interventions in irritable bowel syndrome: a meta-analysis of randomised controlled trials. Benef Microbes 13:183–194
pubmed: 35848115
doi: 10.3920/BM2021.0123
Bian LQ, Lu F, Li ZH, Ll BS, Gao R, Wang FY et al (2016) Analysis of response of IBS-SSS, AR, and IBS-QOL in IBS clinical effect evaluation. Zhongguo Zhong Xi Yi Jie He Za Zhi 36:1191–1196
pubmed: 30641005
Passos MC, Lembo AJ, Conboy LA, Kaptchuk TJ, Kelly JM, Quilty MT et al (2009) Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol 104:912–919
pubmed: 19293784
pmcid: 2707022
doi: 10.1038/ajg.2009.13
Betz C, Mannsdorfer K, Bischoff SC (2013) Validation of the IBS-SSS. Z Gastroenterol 51:1171–1176
pubmed: 24122378
doi: 10.1055/s-0033-1335260